Citadel Advisors’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-36,554
| Closed | -$15K | – | 10377 |
|
|
2018
Q4 | $15K | Buy |
+36,554
| New | +$22.7K | ﹤0.01% | 8850 |
|
|
2018
Q3 | – | Sell |
-12,022
| Closed | -$20.1K | – | 10126 |
|
|
2018
Q2 | $29K | Buy |
+12,022
| New | +$29.4K | ﹤0.01% | 8577 |
|
|
2017
Q1 | – | Sell |
-40,863
| Closed | -$79K | – | 8539 |
|
|
2016
Q4 | $79K | Buy |
40,863
+28,165
| +222% | +$102K | ﹤0.01% | 6758 |
|
|
2016
Q3 | $79K | Buy |
+12,698
| New | +$78.3K | ﹤0.01% | 6725 |
|
|
2016
Q1 | – | Sell |
-364
| Closed | -$11K | – | 8919 |
|
|
2015
Q4 | $11K | Sell |
364
-2,778
| -88% | -$84K | ﹤0.01% | 8253 |
|
|
2015
Q3 | $99K | Sell |
3,142
-28,209
| -90% | -$1.35M | ﹤0.01% | 6970 |
|
|
2015
Q2 | $1.86M | Buy |
31,351
+13,360
| +74% | +$942K | ﹤0.01% | 3149 |
|
|
2015
Q1 | $1.92M | Buy |
17,991
+6,817
| +61% | +$650K | ﹤0.01% | 3111 |
|
|
2014
Q4 | $1.05M | Buy |
11,174
+10,087
| +928% | +$962K | ﹤0.01% | 3709 |
|
|
2014
Q3 | $83K | Sell |
1,087
-660
| -38% | -$52K | ﹤0.01% | 6570 |
|
|
2014
Q2 | $157K | Buy |
+1,747
| New | +$107K | ﹤0.01% | 5827 |
|
Citadel Advisors's PTX Position: Q1 2019 in Review
Citadel Advisors sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 36,554 shares — an estimated $15K sold.
Citadel Advisors first reported a position in PTX in Q2 2014 and held it in 11 quarters. The position peaked at $1.92M in Q1 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.
- Citadel Advisors reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
- Citadel Advisors sold 36,554 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $15K.
- Citadel Advisors first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2014 and held it in 11 quarters.
- Citadel Advisors's Pernix Therapeutics Holdings, Inc. position peaked at $1.92M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.
Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.